Semaglutide Effects on Sperm Concentration in Overweight Infertile Men (SemenGlutide)

November 16, 2026 updated by: Martin Blomberg Jensen, Copenhagen University Hospital at Herlev

SemenGlutide: A Randomised Double-Blinded, Placebo-Controlled, Single-Center, Clinical Trial Comparing the Effects of S.C. Semaglutide 2.4 Mg Once-Weekly Versus Placebo on Sperm Concentration in Overweight Infertile Men

Overweight and obesity are associated with functional hypogonadism and impaired semen quality. Although lifestyle interventions may improve reproductive function, long-term adherence is often challenging. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), increasingly used to treat obesity, have shown promising effects on weight loss, testosterone levels and potentially semen quality through both direct and indirect mechanisms. However, clinical evidence regarding their effects on male fertility remains limited.

The SemenGlutide trial is a randomised, double-blinded, placebo-controlled, single-centre clinical trial investigating whether once-weekly subcutaneous semaglutide improves semen quality in overweight infertile men, compared with placebo.

Study Overview

Status

Not yet recruiting

Detailed Description

It is estimated that around 10-20 percentage of couples worldwide experience infertility. In up to 30-50 percent of these cases, the male is a significant contributing factor. Very few new treatment modalities are being developed to improve semen quality or sperm function despite the significant male contribution to the infertility problem and the observed global decline in semen quality. While assisted reproductive technology (ART) has improved tremendously, these techniques only focus on treating the female even when the male is the only cause of infertility. While infertility is defined at the couple level, male fertility potential is typically evaluated by routine semen analyses where sperm concentration, sperm motility and morphology are assessed. Men with overweight often struggle with functional hypogonadism and possible direct testicular effects resulting in impaired semen quality. Functional hypogonadism is a potentially reversible condition characterised by mild to moderately low testosterone levels with low-to-normal luteinizing hormone (LH) levels thought to originate from age and/or lifestyle-related comorbidities, including obesity and metabolic syndrome. To maintain normal spermatogenesis, a functioning hypothalamic-pituitary-gonadal (HPG) axis is required. It is known that obesity can affect and impair the HPG axis, however, the mechanism of the proposed potential concomitant impaired semen quality has been discussed regarding inflammation or the direct effect of an impaired HPG-axis, playing the main role. Overweight and obese men have functional or hypogonadotropic hypogonadism phenotype that can lead to reduced semen quality. Lifestyle interventions can be effective, but compliance with these interventions is difficult, and many men fail in the long term. Recent advances in knowledge of the effects of glucagon-like peptide-1 receptor agonists (GLP-1RA) suggest that this class of drugs can improve hypogonadism and maybe also semen quality in overweight and obese men by both direct and indirect effects. GLP-1RAs are being used more frequently, and new roles in non-classical targets are emerging. A recent systematic review and meta-analysis investigating the effect of GLP-1RAs on testosterone in males suffering from overweight/obesity showed that treatment with GLP-1RAs resulted in weight loss, improved testicular function and a possible favourable effect on testosterone and gonadotropins. Considering this, weight loss medication is possibly a favourable tool to use in overweight patients with male infertility irrespective of the presence of obesity. GLP-1RA, Semaglutide, is approved for the management of overweight/obesity in doses up to 2.4 mg and induces substantial weight loss. GLP-1RA administration increases hypothalamic kisspeptin expression and stimulates gonadotropin-releasing hormone (GnRH) secretion in rodent studies. In addition, Semaglutide may have a direct testicular effect that appears to be beneficial, as shown by data from the Division of Translational Endocrinology, Herlev but also a study by Signe Torekovs group showing improved semen quality in men with normal fertility following weight loss and liraglutide treatment.

SemenGlutide is a randomised double-blinded, placebo-controlled, single-center, clinical trial comparing the effects of subcutaneous (s.c.) Semaglutide 2.4 mg once-weekly versus placebo on sperm concentration in overweight infertile men. The study aims to investigate whether semaglutide can improve semen quality in infertile men with a body mass index (BMI) of at least 27 kg/m^2. The hypothesis is that semaglutide treatment will result in a greater increase in sperm production compared with placebo.

Following confirmation of eligibility and obtained informed consent, participants will be randomised at baseline in a 1.5:1 ratio to receive either semaglutide or placebo. Participants will receive the study medication for self-administration at home throughout the trial, with regular dispensing by trained study personnel. The dose will be gradually titrated to the target dose of 2.4 mg semaglutide or corresponding placebo. A total of 150 men will be enrolled, with at least 120 expected to complete the trial. This sample size will provide 80 percent power to detect a 65 percent greater increase in sperm concentration in the semaglutide group compared with placebo at day 200, using a significance level of 5 percent.

Safety is evaluated throughout the study using repeated clinical assessments, laboratory monitoring, and systematic recording of adverse events. All side effects will be closely monitored and reported. The study is approved by the regional ethical committee, conducted in compliance with The Declaration of Helsinki and monitored by the Good Clinical Practice unit of Copenhagen University Hospitals.

Study Type

Interventional

Enrollment (Estimated)

150

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Herlev, Denmark, 2730
        • Division of Translational Endocrinology, Department of Endocrinology and Internal Medicine, Copenhagen University Hospital Herlev.
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
  • Men 18 to 60 years of age (both inclusive) at the time of signing informed consent.
  • Infertile men with at least one altered semen parameter (Sperm concentration < 16 million/mL, or percentage of motile spermatozoa < 42%, or percentage of morphologically normal spermatozoa < 4%)
  • Body mass index (BMI) ≥ 27 kg/m^2

Exclusion Criteria:

  • Type 1 diabetes
  • Total sperm count >80 million
  • Sperm concentration < 1 million/mL
  • BMI > 50 kg/m^2
  • Estimated glomerular filtration rate (eGFR) <45 ml/min/1.73 m^2
  • Known chromosomal aberrations (except minor Y-chromosome deletions)
  • Detected cystic fibrosis transmembrane conductance regulator (CFTR) mutation
  • Treatment with glucagon-like peptide-1-receptor-agonist (GLP-1RA) 6 months prior to inclusion
  • Any disorder which in the investigator's opinion might jeopardize participant's safety or compliance with the protocol
  • Obesity related to endocrinologic disorders (e.g., Cushing's syndrome)
  • Use of any prescription or non-prescription medication (apart from routine vitamins, occasional use of paracetamol, acetylsalicylic acid, or ibuprofen) which could interfere with pharmacokinetic or pharmacodynamic results, as judged by the investigator, such as: Herbal products and non-routine vitamins , Insulin, medication that may cause weight gain (including systemic corticosteroids, tricyclic antidepressants, and atypical antipsychotics), orlistat, zonisamide, topiramate, phentermine, lorcaserin, bupropion, naltrexone or other weight loss drugs. Blood pressure and lipid lowering agents (e.g., statins) drugs are allowed if treatment has been stable for ≥ 1 month prior to screening at visit 0.
  • History of pancreatitis (acute or chronic)
  • Daily use of morphine
  • Surgery scheduled for the trial duration period, except for minor, non-gastrointestinal surgical procedures at the discretion of the investigator
  • History of bariatric surgery
  • Cancer (past or present, except basal cell skin cancer or squamous cell skin cancer), which in the investigator's opinion could interfere with the results of the trial
  • Inability or unwillingness to perform self-injection at the screening visit (with a placebo test pen)
  • Mental incapacity, language barriers or unwillingness to comply with the requirements of the protocol, which may preclude adequate understanding or co-operation during the trial, as judged by the investigator
  • Dysregulated type 2 diabetes judged by the investigators
  • Serum follicle-stimulating hormone (FSH) <2 IU/L

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Semaglutide

Semaglutide 2.4 mg administered subcutaneously once weekly

Titration algorithms are used in order to ensure participants receive optimal treatment with minimal side-effects. Patients will recieve full dosage of 2.4mg a week from week 16 to week 43.

Placebo Comparator: Placebo

Saline administered subcutaneously once weekly

Titration algorithms similar to those used in the intervention group will be applied to maintain blinding. Participants will receive the full target dose once weekly from week 16 to week 43.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference in sperm concentration or total sperm count on day 200
Time Frame: From baseline to day 200

Difference in sperm production evaluated by sperm concentration (millions/mL) or total sperm count (millions) measured by semen analysis.

From baseline to day 200

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference in sperm concentration from baseline to day 300
Time Frame: From baseline to day 300

Difference in sperm concentration (millions/mL) evaluated by semen analysis

From baseline to day 300
Differences and changes in DNA fragmentation index (%) from baseline to day 300
Time Frame: From baseline to day 200 and 300
From baseline to day 200 and 300
Changes in sperm parameters from baseline to day 300
Time Frame: From baseline to day 100, 200 and 300

Measured by number (millions)

From baseline to day 100, 200 and 300
Differences in sperm production from baseline to day 300
Time Frame: From baseline to day 200 and 300

Sperm concentration (million/mL) evaluated by the automated CASA SCA (Microptic) system

From baseline to day 200 and 300
Differences in body mass index (BMI) from baseline to day 300
Time Frame: From baseline to day 100, 200 and 300

Weight (kg) and height (cm) is measured at each visit during the trial, and will be combined to report BMI

From baseline to day 100, 200 and 300
Differences in total body fat percentage (%) from baseline to day 300
Time Frame: From baseline to day 300

Evaluated by dual-energy x-ray absorptiometry (DXA) scan

From baseline to day 300
Differences in bone mineral density (BMD) g/cm^2 from baseline to day 300
Time Frame: From baseline to day 300

Evaluated by DXA scan

From baseline to day 300
Changes in subjective symptoms of androgen deficiency from baseline to day 300
Time Frame: From baseline to day 300

Assessed using Androgen Deficiency in the Aging Male questionnaire (ADAM). The summation of the responses yields a total ADAM score between 10 and 50, with 10 being most symptomatic and 50 being least symptomatic.

From baseline to day 300
Changes in male sexual function from baseline to day 300
Time Frame: From baseline to day 300

Assessed using The International Index of Erectile Function questionnaire (IIEF-5). The possible scores for the IIEF-5 range from 5 to 25, and erectile dysfunction (ED) is classified into five categories based on the scores: severe (5-7), moderate (8-11), mild to moderate (12-16), mild (17-21), and no ED (22-25).

From baseline to day 300
Changes in total testosterone (nmol/L) and free testosterone (nmol/L) from baseline to day 300
Time Frame: From baseline to day 100, day 200 and day 300

Measured by blood sample

From baseline to day 100, day 200 and day 300
Differences in luteinizing hormone (IU/L) and follicel stimulating hormone (IU/L) from baseline to day 300
Time Frame: From baseline to day 100, day 200 and day 300

Measured by bloodsample.

From baseline to day 100, day 200 and day 300
Differences in HbA1c from baseline to day 300
Time Frame: From baseline to day 100, day 200 and day 300

Measured by bloodsample.

From baseline to day 100, day 200 and day 300
Differences in lipid profile from baseline to day 300
Time Frame: From baseline to day 100, day 200 and day 300

Differences in total cholesterol (mmol/L), high-density lipoprotein cholesterol (mmol/L), low-density lipoprotein cholesterol (mmol/L) and triglycerides (mmol/L). Measured by bloodsample.

From baseline to day 100, day 200 and day 300
Changes in sperm parameters from baseline to day 300
Time Frame: From baseline to day 100, 200 and 300

Measured by motility (%) by semen analysis

From baseline to day 100, 200 and 300
Changes in sperm parameters from baseline to day 300
Time Frame: From baseline to day 100, 200 and 300

Measured by morphology (%) by semen analysis

From baseline to day 100, 200 and 300
Differences in sperm production from baseline to day 300
Time Frame: From baseline to day 200 and 300

Total sperm count (million) evaluated by the automated CASA SCA (Microptic) system

From baseline to day 200 and 300
Differences in sperm production from baseline to day 300
Time Frame: From baseline to day 200 and 300

Total motile sperm (%) evaluated by the automated CASA SCA (Microptic) system

From baseline to day 200 and 300
Differences in total muscle mass (kg) from baseline to day 300
Time Frame: From baseline to day 300

Evaluated by DXA scan

From baseline to day 300
Differences in trabecular bone score (TBS) from baseline to day 300
Time Frame: From baseline to day 300

Evaluated by DXA scan. A normal TBS is defined as >1.350 (no units) where TBS bewteen 1.200 and 1.350 is defined as partially degraded bone.

From baseline to day 300
Differences in sex hormone binding globulin (SHBG) (nmol/L) from baseline to day 300
Time Frame: From baseline to day 100, day 200 and day 300

Measured by bloodsample.

From baseline to day 100, day 200 and day 300
Differences in Anti-Müllerian Hormone (AMH) (pmol/L) from baseline to day 300
Time Frame: From baseline to day 100, day 200 and day 300

Measured by bloodsample.

From baseline to day 100, day 200 and day 300
Differences in inhibin B (ng/L) from baseline to day 300
Time Frame: From baseline to day 100, day 200 and day 300

Measured by bloodsample.

From baseline to day 100, day 200 and day 300
Differences in HOMA-IR from baseline to day 300
Time Frame: From baseline to day 100, day 200 and day 300

HOMA-IR will be calculated as follows:

(plasma insulin (µIU/mL) × plasma glucose (mg/dL)) / 405 = HOMA-IR.

Values <1.0 indicate optimal insulin sensitivity, 1.0-1.9 indicate mild insulin resistance, 2.0-2.9 indicate moderate insulin resistance, and >3.0 indicate significant insulin resistance.

From baseline to day 100, day 200 and day 300

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in circulating markers of bone resorption and formation from baseline to day 300
Time Frame: From baseline to day 100, day 200 and day 300

Changes in procollagen type I N-terminal propeptide (PINP), Receptor Activator of Nuclear Factor κB Ligand (RANKL), Osteoprotegerin (OPG) and C-terminal telopeptide of type I collagen (CTX) measured by bloodsample

From baseline to day 100, day 200 and day 300
Changes in calcium homeostasis and spoturine from baseline to day 300
Time Frame: From baseline to day 100, day 200 and day 300

Measured by serum (albumin, calcium, phosphate) and urine (calcium, iron, ferritin, zinc, magnesium, phosphate, sodium and creatinine)

From baseline to day 100, day 200 and day 300
Change in mineral homeostasis from baseline to day 300
Time Frame: From baseline to day 100, day 200 and day 300

Changes in serum iron, ferritin, hepcidin, transferrin, magnesium, zinc, measured by bloodsample

From baseline to day 100, day 200 and day 300
Changes in calciotropic hormones from baseline to day 300
Time Frame: From baseline to day 100, day 200 and day 300

Changes in serum 25OHD, parathyroid hormone (PTH), Klotho and fibroblast growth factor 23 (FGF23), measured by bloodsample

From baseline to day 100, day 200 and day 300
Changes in serum vitamin D metabolites from baseline to day 300
Time Frame: From baseline to day 100, day 200 and day 300

Changes in serum cholecalciferol, 25OHD, 24,25OHD 1,25OHD and cholecalciferol/25OHD ratio, 25OHD/24,25OHD ratio, measured by bloodsample

From baseline to day 100, day 200 and day 300
Changes in androstenedione, progesterone, cortisol, cortisone and dehydroepiandrosterone sulfate (DHEAS) from baseline to day 300
Time Frame: From baseline to day 100, day 200 and day 300

Measured by bloodsample

From baseline to day 100, day 200 and day 300
Changes in 11-oxy-androgens and androgens from the alternative pathway from baseline to day 300
Time Frame: From baseline to day 100, day 200 and day 300

Measured by bloodsample

From baseline to day 100, day 200 and day 300
Changes in thyroid stimulating hormone (TSH), T3, T4, CBG, TBG, INSL-3, Prolactin from baseline to day 300
Time Frame: From baseline to day 100, day 200 and day 300

Measured by bloodsample

From baseline to day 100, day 200 and day 300
Changes in seminal fluid of minerals and hormones from baseline to day 300
Time Frame: From baseline to day 100, day 200 and day 300

Seminal fluid

From baseline to day 100, day 200 and day 300

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

June 1, 2029

Study Completion (Estimated)

October 1, 2029

Study Registration Dates

First Submitted

November 9, 2026

First Submitted That Met QC Criteria

November 16, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe